Does the media prefer ZVRA or TNXP?

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.47 beat Tonix Pharmaceuticals' score of 0.36 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to CYRX or TNXP?

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat Tonix Pharmaceuticals' score of 0.36 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, TNXP or IVA?

Tonix Pharmaceuticals has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tonix Pharmaceuticals $13.11M 15.50 -$124.02M -$14.36 N/A Inventiva $4.48M 164.48 -$400.67M N/A N/A

Does the media favor TNXP or RLMD?

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.57 beat Tonix Pharmaceuticals' score of 0.36 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TNXP or ALLO?

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.69 beat Tonix Pharmaceuticals' score of 0.36 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tonix Pharmaceuticals (TNXP) Competitors

$12.75 -0.47 (-3.56%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$12.82 +0.06 (+0.51%)

As of 07:35 AM Eastern

Compare

TNXP vs. ZVRA, CYRX, IVA, RLMD, and ALLO

Should you buy Tonix Pharmaceuticals stock or one of its competitors? MarketBeat compares Tonix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tonix Pharmaceuticals include Zevra Therapeutics (ZVRA), CryoPort (CYRX), Inventiva (IVA), Relmada Therapeutics (RLMD), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

In the previous week, Tonix Pharmaceuticals had 4 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.47 beat Tonix Pharmaceuticals' score of 0.36 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics presently has a consensus target price of $29.29, suggesting a potential upside of 109.03%. Tonix Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 88.24%. Given Zevra Therapeutics' higher probable upside, equities analysts plainly believe Zevra Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Zevra Therapeutics has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	6.77	$83.23M	$1.99	7.04
Tonix Pharmaceuticals	$13.11M	15.50	-$124.02M	-$14.36	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Tonix Pharmaceuticals' net margin of -839.52%. Zevra Therapeutics' return on equity of 51.49% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

Summary

Zevra Therapeutics beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

CryoPort currently has a consensus target price of $15.11, suggesting a potential downside of 7.18%. Tonix Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 88.24%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

92.9% of CryoPort shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 10.1% of CryoPort shares are held by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Tonix Pharmaceuticals had 2 more articles in the media than CryoPort. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat Tonix Pharmaceuticals' score of 0.36 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tonix Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

CryoPort has a net margin of 41.57% compared to Tonix Pharmaceuticals' net margin of -839.52%. CryoPort's return on equity of -7.92% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%

CryoPort has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

CryoPort has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.66	$78.30M	$1.35	12.06
Tonix Pharmaceuticals	$13.11M	15.50	-$124.02M	-$14.36	N/A

Summary

CryoPort beats Tonix Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Inventiva?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Inventiva has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Inventiva's return on equity of 0.00% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Inventiva	N/A	N/A	N/A

Tonix Pharmaceuticals currently has a consensus target price of $24.00, indicating a potential upside of 88.24%. Inventiva has a consensus target price of $16.56, indicating a potential upside of 366.35%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tonix Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Tonix Pharmaceuticals has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	15.50	-$124.02M	-$14.36	N/A
Inventiva	$4.48M	164.48	-$400.67M	N/A	N/A

In the previous week, Tonix Pharmaceuticals had 6 more articles in the media than Inventiva. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 1 mentions for Inventiva. Tonix Pharmaceuticals' average media sentiment score of 0.36 beat Inventiva's score of 0.30 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Tonix Pharmaceuticals	Neutral
Inventiva	Neutral

Summary

Inventiva beats Tonix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tonix Pharmaceuticals presently has a consensus price target of $24.00, indicating a potential upside of 88.24%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 71.92%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Tonix Pharmaceuticals has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

In the previous week, Tonix Pharmaceuticals had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 4 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.57 beat Tonix Pharmaceuticals' score of 0.36 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	15.50	-$124.02M	-$14.36	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Relmada Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Tonix Pharmaceuticals' return on equity of -67.65% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Tonix Pharmaceuticals beats Relmada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Tonix Pharmaceuticals (NASDAQ:TNXP) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Tonix Pharmaceuticals and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.69 beat Tonix Pharmaceuticals' score of 0.36 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tonix Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tonix Pharmaceuticals has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tonix Pharmaceuticals	$13.11M	15.50	-$124.02M	-$14.36	N/A
Allogene Therapeutics	$20K	38,311.65	-$190.89M	-$0.77	N/A

Tonix Pharmaceuticals has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -839.52%. Allogene Therapeutics' return on equity of -56.45% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tonix Pharmaceuticals	-839.52%	-67.65%	-60.47%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Tonix Pharmaceuticals presently has a consensus price target of $24.00, indicating a potential upside of 88.24%. Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 283.88%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 2.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Tonix Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Tonix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNXP vs. The Competition

Export

Metric	Tonix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$210.74M	$3.02B	$6.84B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-0.89	19.67	25.79	24.54
Price / Sales	15.50	336.48	539.82	100.81
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	0.67	4.25	10.88	6.49
Net Income	-$124.02M	$64.45M	$3.57B	$336.61M
7 Day Performance	6.61%	3.73%	2.47%	1.20%
1 Month Performance	3.41%	4.01%	0.84%	0.20%
1 Year Performance	-64.56%	34.35%	36.37%	30.15%

Tonix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNXP Tonix Pharmaceuticals	4.1539 of 5 stars	$12.75 -3.6%	$24.00 +88.2%	-63.5%	$210.74M	$13.11M	N/A	50	News Coverage
ZVRA Zevra Therapeutics	4.4975 of 5 stars	$12.90 flat	$29.29 +127.0%	+55.7%	$762.65M	$106.47M	6.48	20
CYRX CryoPort	3.8144 of 5 stars	$15.01 flat	$15.11 +0.7%	+119.7%	$756.50M	$176.18M	11.12	1,186	Positive News
IVA Inventiva	2.6562 of 5 stars	$3.57 flat	$16.56 +363.7%	+16.9%	$741.53M	$5.07M	N/A	100	Gap Up High Trading Volume
RLMD Relmada Therapeutics	2.1726 of 5 stars	$6.73 flat	$12.00 +78.3%	+1,044.3%	$705.91M	N/A	N/A	10	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNXP) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. ZVRA, CYRX, IVA, RLMD, and ALLO

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to CryoPort?

Summary

How does Tonix Pharmaceuticals compare to Inventiva?

Summary

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tonix Pharmaceuticals (TNXP) Competitors

TNXP vs. ZVRA, CYRX, IVA, RLMD, and ALLO

How does Tonix Pharmaceuticals compare to Zevra Therapeutics?

Does the media prefer ZVRA or TNXP?

Do insiders & institutionals hold more shares of ZVRA or TNXP?

Do analysts rate ZVRA or TNXP?

Which has stronger earnings & valuation, ZVRA or TNXP?

Is ZVRA or TNXP more profitable?

Which has more volatility & risk, ZVRA or TNXP?

Summary

How does Tonix Pharmaceuticals compare to CryoPort?

Do analysts recommend CYRX or TNXP?

Do insiders & institutionals have more ownership in CYRX or TNXP?

Does the media refer more to CYRX or TNXP?

Is CYRX or TNXP more profitable?

Which has more risk & volatility, CYRX or TNXP?

Which has better valuation & earnings, CYRX or TNXP?

Summary

How does Tonix Pharmaceuticals compare to Inventiva?

Is TNXP or IVA more profitable?

Do analysts recommend TNXP or IVA?

Do institutionals and insiders believe in TNXP or IVA?

Which has more risk and volatility, TNXP or IVA?

Which has stronger earnings and valuation, TNXP or IVA?

Does the media favor TNXP or IVA?

Summary

How does Tonix Pharmaceuticals compare to Relmada Therapeutics?

Do institutionals & insiders believe in TNXP or RLMD?

Do analysts recommend TNXP or RLMD?

Which has more volatility and risk, TNXP or RLMD?

Does the media favor TNXP or RLMD?

Which has better valuation and earnings, TNXP or RLMD?

Is TNXP or RLMD more profitable?

Summary

How does Tonix Pharmaceuticals compare to Allogene Therapeutics?

Does the media favor TNXP or ALLO?

Which has preferable valuation and earnings, TNXP or ALLO?

Which has more risk & volatility, TNXP or ALLO?

Is TNXP or ALLO more profitable?

Do analysts rate TNXP or ALLO?

Do insiders and institutionals believe in TNXP or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP vs. The Competition

Tonix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools